Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 8, 2008, Pages 3158-3164

  Mauger, Jean François ^a   Lévesque, Josée ^a   Paradis, Marie Eve ^a   Bergeron, Nathalie ^b   Tchernof, André ^c   Couture, Patrick ^c   Lamarche, Benoît ^a  

^a LAVAL UNIVERSITY   (Canada)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; ISOTOPE; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; INFUSION; KINETICS; MALE; MASS FRAGMENTOGRAPHY; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; SEX; STATISTICAL SIGNIFICANCE; TIME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 49249093092     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2585     Document Type: Article

References (34)

1. Fischer CL, Gill C, Forrester MG, Nakamura R 1976 Quantitation of "acute-phase proteins" postoperatively. Value in detection and monitoring of complications. Am J Clin Pathol 66:840-846
2. Getz GS 2005 Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res 46:1-10
3. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB 2000 Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321:199-204
4. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK 2002 C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 144:233-238
5. Kuller LH, Tracy RP, Shaten J, Meilahn EN 1996 Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144:537-547
6. Ridker PM, Hennekens CH, Buring JE, Rifai N 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843
7. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V 2004 C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397
8. Lowe GD, Pepys MB 2006 C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 8:421-428
9. Fogli-Cawley JJ, Dwyer JT, Saltzman E, McCullough ML, Troy LM, Meigs JB, Jacques PF 2007 2005 The dietary guidelines for Americans and risk of the metabolic syndrome. Am J Clin Nutr 86:1193-1201
10. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J 2005 The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295-300
11. Nash DT 2005 Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. J Natl Med Assoc 97:1600-1607
12. Rutter MK, Meigs JB, Sullivan LM, D'Agostino Sr RB, Wilson PW 2004 C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380-385
13. Ford ES, Ajani UA, Mokdad AH 2005 The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 28:878-881
14. Garcia-Lorda P, Bullo M, Balanza R, Salas-Salvado J 2006 C-reactive protein, adiposity and cardiovascular risk factors in a Mediterranean population. Int J Obes (Lond) 30:468-474
15. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W 2000 Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835-1839
16. Lara-Castro C, Fu Y, Chung BH, Garvey WT 2007 Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18:263-270
17. Desroches S, Archer WR, Paradis ME, Deriaz O, Couture P, Bergeron J, Bergeron N, Lamarche B 2006 Baseline plasma C-reactive protein concentrations influence lipid and lipoprotein responses to low-fat and high monounsaturated fatty acid diets in healthy men. J Nutr 136:1005-1011
18. Archer WR, Lamarche B, Deriaz O, Landry N, Corneau L, Despres JP, Bergeron J, Couture P, Bergeron N 2003 Variations in body composition and plasma lipids in response to a high-carbohydrate diet. Obes Res 11:978-986
19. An P, Rice T, Gagnon J, Borecki IB, Bergeron J, Despres JP, Leon AS, Skinner JS, Wilmore JH, Bouchard C, Rao DC 2000 Segregation analysis of apolipoproteins A-1 and B-100 measured before and after an exercise training program: the HERITAGE Family Study. Arterioscler Thromb Vasc Biol 20:807-814
20. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
21. Bouchard L, Vohl MC, Deshaies Y, Rheaume C, Daris M, Tchernof A 2007 Visceral adipose tissue zinc finger protein 36 mRNA levels are correlated with insulin, insulin resistance index, and adiponectinemia in women. Eur J Endocrinol 157:451-457
22. Mauger JF, Couture P, Paradis ME, Lamarche B 2005 Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis 178:157-163
23. Ramakrishnan R 2006 Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments. J Lipid Res 47:2738-2753
24. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ 1990 Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 85:804-811
25. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJ, Anker SD 2002 The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 39:1901-1908
26. Vigushin DM, Pepys MB, Hawkins PN 1993 Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91:1351-1357
27. Ruel IL, Couture P, Cohn JS, Lamarche B 2005 Plasma metabolism of apoB-containing lipoproteins in patients with hepatic lipase deficiency. Atherosclerosis 180:355-366
28. Ikewaki K, Zech LA, Brewer HB Jr., Rader DJ 1996 ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. J Lipid Res 37:399-407
29. Beltz WF, Kesaniemi YA, Miller NH, Fisher WR, Grundy SM, Zech LA 1990 Studies on the metabolism of apolipoprotein B in hypertriglyceridemic subjects using simultaneous administration of tritiated leucine and radioiodinated very low density lipoprotein. J Lipid Res 31:361-374
30. Ooi EM, Watts GF, Farvid MS, Chan DC, Allen MC, Zilko SR, Barrett PH 2006 High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. Eur J Clin Invest 36:626-632
31. Pepys MB, Hirschfield GM 2003 C-reactive protein: a critical update. J Clin Invest 111:1805-1812
32. Blackburn P, Despres JP, Lamarche B, Tremblay A, Bergeron J, Lemieux I, Couillard C 2006 Postprandial variations of plasma inflammatory markers in abdominally obese men. Obesity (Silver Spring) 14:1747-1754
33. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y 2004 Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28:674-679
34. Trujillo ME, Scherer PE 2005 Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257:167-175